000 02385 a2200649 4500
005 20250517151632.0
264 0 _c20170824
008 201708s 0 0 eng d
022 _a1474-5488
024 7 _a10.1016/S1470-2045(17)30279-6
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aColeman, Robert L
245 0 0 _aBevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
_h[electronic resource]
260 _bThe Lancet. Oncology
_c06 2017
300 _a779-791 p.
_bdigital
500 _aPublication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
650 0 4 _aAdult
650 0 4 _aAged
650 0 4 _aAged, 80 and over
650 0 4 _aAntineoplastic Combined Chemotherapy Protocols
_xadverse effects
650 0 4 _aBevacizumab
_xadministration & dosage
650 0 4 _aCarboplatin
_xadministration & dosage
650 0 4 _aCarcinoma, Ovarian Epithelial
650 0 4 _aCytoreduction Surgical Procedures
650 0 4 _aDisease-Free Survival
650 0 4 _aFallopian Tube Neoplasms
_xtherapy
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aMiddle Aged
650 0 4 _aNeoplasm Recurrence, Local
_xtherapy
650 0 4 _aNeoplasms, Glandular and Epithelial
_xtherapy
650 0 4 _aOvarian Neoplasms
_xtherapy
650 0 4 _aPaclitaxel
_xadministration & dosage
650 0 4 _aPeritoneal Neoplasms
_xtherapy
650 0 4 _aSurvival Rate
650 0 4 _aYoung Adult
700 1 _aBrady, Mark F
700 1 _aHerzog, Thomas J
700 1 _aSabbatini, Paul
700 1 _aArmstrong, Deborah K
700 1 _aWalker, Joan L
700 1 _aKim, Byoung-Gie
700 1 _aFujiwara, Keiichi
700 1 _aTewari, Krishnansu S
700 1 _aO'Malley, David M
700 1 _aDavidson, Susan A
700 1 _aRubin, Stephen C
700 1 _aDiSilvestro, Paul
700 1 _aBasen-Engquist, Karen
700 1 _aHuang, Helen
700 1 _aChan, John K
700 1 _aSpirtos, Nick M
700 1 _aAshfaq, Raheela
700 1 _aMannel, Robert S
773 0 _tThe Lancet. Oncology
_gvol. 18
_gno. 6
_gp. 779-791
856 4 0 _uhttps://doi.org/10.1016/S1470-2045(17)30279-6
_zAvailable from publisher's website
999 _c27109157
_d27109157